{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T07:58:58Z","timestamp":1779263938377,"version":"3.51.4"},"reference-count":16,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T00:00:00Z","timestamp":1428883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Ministry of Sport of the Russian Federation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p>Growth hormone releasing peptides (GHRPs) stimulate secretion of endogenous growth hormone and are listed on the World Anti\u2010Doping Agency (WADA) Prohibited List. To develop an effective method for GHRPs anti\u2010doping control we have investigated metabolites of GHRP\u20101, GHRP\u20102, GHRP\u20106, Hexarelin, and Ipamorelin in urine after nasal administration. Each compound was administrated to one volunteer. Samples were collected for 2 days after administration, processed by solid\u2010phase extraction on weak cation exchange cartridges and analyzed by means of nano\u2010liquid chromatography \u2010 high resolution mass spectrometry. Six metabolites of GHRP\u20101 were identified. GHRP\u20101 in the parent form was not detected. GHRP\u20101 (2\u20104) free acid was detected in urine up to 27 h. GHRP\u20102, GHRP\u20102 free acid and GHRP\u20102 (1\u20103) free acid were detected in urine up to 47 h after administration. GHRP\u20106 was mostly excreted unchanged and detected in urine 23 h after administration, its metabolites were detectable for 12 h only. Hexarelin and Ipamorelin metabolized intensively and were excreted as a set of parent compounds with metabolites. Hexarelin (1\u20103) free acid and Ipamorelin (1\u20104) free acid were detected in urine samples after complete withdrawal of parent substances. GHRPs and their most prominent metabolites were included into routine ultra\u2010pressure liquid chromatography\u2010tandem mass spectrometry procedure. The method was fully validated, calibration curves of targeted analytes were obtained and excretion curves of GHRPs and their metabolites were plotted. Our results confirm that the detection window after GHRPs administration depends on individual metabolism, drug preparation form and the way of administration. Copyright \u00a9 2015 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/dta.1787","type":"journal-article","created":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T01:41:53Z","timestamp":1428975713000},"page":"919-925","source":"Crossref","is-referenced-by-count":44,"title":["Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP\u20101, GHRP\u20102, GHRP\u20106, Hexarelin, and Ipamorelin"],"prefix":"10.1002","volume":"7","author":[{"given":"Ekaterina","family":"Semenistaya","sequence":"first","affiliation":[{"name":"Anti\u2010Doping Center  Elizavetinskiy per., 10\/1 Moscow 105005 Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Zvereva","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Center  Elizavetinskiy per., 10\/1 Moscow 105005 Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Thomas","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Center for Preventive Doping Research German Sport University Cologne  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Thevis","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Center for Preventive Doping Research German Sport University Cologne  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grigory","family":"Krotov","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Center  Elizavetinskiy per., 10\/1 Moscow 105005 Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grigory","family":"Rodchenkov","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Center  Elizavetinskiy per., 10\/1 Moscow 105005 Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,4,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(97)00016-8"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.domaniend.2005.02.033"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.166"},{"key":"e_1_2_6_5_1","unstructured":"WADA.Prohibited list. Available at:http:\/\/www.wada\u2010ama.org\/Documents\/World_Anti\u2010Doping_Program\/WADP\u2010Prohibited\u2010list\/2014\/WADA\u2010prohibited\u2010list\u20102014\u2010EN.pdf[24 November 2014]."},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2012.10.006"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-011-4702-3"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-011-5544-8"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1624"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1734"},{"key":"e_1_2_6_11_1","unstructured":"Canadian Centre for Ethics in Sports vs. Jordan Arkko. Available at:http:\/\/www.crdsc\u2010sdrcc.ca\/resource_centre\/pdf\/English\/0_SDRCC%20DT%2014\u20100206.pdf[06 February 2015]."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac302034w"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.4619"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/004982598238976"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1550079"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj1954.38.15"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.78.3.693"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.1787","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.1787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T03:58:57Z","timestamp":1760414337000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.1787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,13]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1002\/dta.1787"],"URL":"https:\/\/doi.org\/10.1002\/dta.1787","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,13]]}}}